Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
- The investigators propose a clinical trial to evaluate the impact of annual shared decision making for PSA screening, supported by system-level enhancements to promote evidence-based care:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Annual PSA Health Maintenance Reminder | Experimental | An annual health maintenance reminder will be implemented for all men who meet the American Cancer Society guidelines for average- and high-risk eligibility criteria. The goal is to encourage their primary care provider (PCP) to engage in a shared decision-making discussion with the patient about the benefits and risks of prostate cancer screening. This alert will appear in the health maintenance reminder section of the electronic health record (EHR). Although all providers with access to EPIC can view the alert, it is typically the PCPs who review and take action on alerts in the health maintenance reminder section. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Annual PSA Health Maintenance Reminder | Other | The annual health maintenance reminder does not mandate PSA screening for eligible patients. Instead, it recommends that primary care providers (PCPs) initiate a shared decision-making discussion with their patients. As part of this conversation, patients will be informed of their individual risk factors-including race, family history, and germline mutations-and can then make an informed choice about whether to proceed with PSA screening. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in PSA screening completion rates in the BJC East Health System | The overall PSA screening rate will be calculated as the number of PSA screening tests that are ordered by PCPs who will receive the alert and completed by patients within a year of the ordering date, divided by the total number of eligible patients. | Through 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of men diagnosed with clinically significant prostate cancer (Gleason score ≥ 7) | Through 5 years | |
| Incidence of advanced and metastatic disease at diagnosis of prostate cancer | Through 5 years |
Not provided
Eligibility Criteria:
Receive care within the BJC Health System
Have had at least one primary care physician appointment in the calendar year of PSA screening (primary care)
Be male
Not have a history of prostate cancer
Meet one of the following risk criteria:
High Risk for Prostate Cancer
Average Risk for Prostate Cancer
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lannis Hall, M.D., MPH | Contact | 636-916-9947 | lannishall@wustl.edu |
| Name | Affiliation | Role |
|---|---|---|
| Lannis Hall, M.D., MPH | Washington University School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Washington University School of Medicine | Recruiting | St Louis | Missouri | 63110 | United States |
Not provided
| Label | URL |
|---|---|
| Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Incidence of early-stage prostate cancer | Through 5 years |
| Stage distribution of prostate cancer diagnoses | Through 5 years |
| Biopsy rates | Through 5 years |
| Percent of PSA screening ordered but not completed | Through 5 years |
| Median PSA at time of diagnosis | Through 5 years |
| Evaluate the agreement between 3T MRI and biomarker test results | The 3T MRI and biomarker tests are used to help determine whether a biopsy is necessary. The investigators will categorize the results as positive versus negative and the agreement will be gauged based on Kappa coefficient. | Through 5 years |
| PSA screening rate by age group | Age groups will include 40-49, 50-70, and 70-75 | Through 5 years |
| PSA screening rate by race | Through 5 years |
| PSA screening rate by comorbidity burden | Through 5 years |
| PSA screening rate by insurance coverage | Through 5 years |
| PSA screening rate by provider | Through 5 years |
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided